Form 4: Castle Biosciences CEO Executes Planned Stock Sales

CEO Derek Maetzold sold shares of Castle Biosciences under a pre-established Rule 10b5-1 trading plan.

Summary

• CEO Derek Maetzold exercised stock options for 550 shares at a strike price of $2.39.
• The exercised shares were subsequently sold alongside additional holdings held in various family trusts.
• Sales occurred on May 20 and May 21, 2026, at weighted-average prices of $20.002 and $20.196 per share, respectively.
• All transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transactions were pre-planned and represent routine portfolio management by the CEO.

Positives

• Transactions were executed under a pre-planned Rule 10b5-1 program, indicating systematic rather than reactive selling.
• The CEO maintains significant beneficial ownership in the company through various trusts and direct holdings.

Negatives

• The filing reflects a reduction in the CEO's direct and indirect equity stake in the company.

Risks

• Continued reliance on Rule 10b5-1 plans for liquidity may lead to periodic selling pressure on the stock.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Management Comments

• The Reporting Person has undertaken to provide full information regarding the number of shares and prices at which the transactions were effected upon request.

Industry Context

StockSavvy.ai notes that routine insider selling under 10b5-1 plans is a standard corporate governance practice and generally does not signal a change in management's outlook on company performance.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for executives to manage personal liquidity while avoiding potential conflicts of interest regarding material non-public information.

Related Party Transactions

• Transactions involved multiple trusts for which the Reporting Person serves as trustee or beneficiary, including the Maetzold Descendants 2020 Trust and various Grantor Retained Annuity Trusts.

Stakeholder Impact

• Minimal impact expected as the sales were executed via a pre-arranged plan.

Next Steps

• Continued monitoring of future Form 4 filings for further transactions under the established 10b5-1 plan.

Key Dates

Keywords

Castle Biosciences, CSTL, Insider Trading, Form 4, Derek Maetzold, Rule 10b5-1